To add to the debate.
Here is the summary of the trial from the NCBI web site. It is a pay for view so I have not had access to the full trial.
It looks like the results were based on tumour tissue analysis of real human patients and not poor mice for a change.
http://www.ncbi.nlm.nih.gov/entrez/...t_uids=15897583
1: Clin Cancer Res. 2005 May 15;11(10):3828-35. Related Articles, Books, LinkOut
Click here to read
Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer.
Thompson LU, Chen JM, Li T, Strasser-Weippl K, Goss PE.
Department of Nutritional Sciences, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada.
PURPOSE: Flaxseed, the richest source of mammalian lignan precursors, has previously been shown to reduce the growth of tumors in rats. This study examined, in a randomized double-blind placebo-controlled clinical trial, the effects of dietary flaxseed on tumor biological markers and urinary lignan excretion in postmenopausal patients with newly diagnosed breast cancer. EXPERIMENTAL DESIGN: Patients were randomized to daily intake of either a 25 g flaxseed-containing muffin (n = 19) or a control (placebo) muffin (n = 13). At the time of diagnosis and again at definitive surgery, tumor tissue was analyzed for the rate of tumor cell proliferation (Ki-67 labeling index, primary end point), apoptosis, c-erbB2 expression, and estrogen and progesterone receptor levels. Twenty-four-hour urine samples were analyzed for lignans, and 3-day diet records were evaluated for macronutrient and caloric intake. Mean treatment times were 39 and 32 days in the placebo and flaxseed groups, respectively. RESULTS: Reductions in Ki-67 labeling index (34.2%; P = 0.001) and in c-erbB2 expression (71.0%; P = 0.003) and an increase in apoptosis (30.7%; P = 0.007) were observed in the flaxseed, but not in the placebo group. No significant differences in caloric and macronutrient intake were seen between groups and between pre- and posttreatment periods. A significant increase in mean urinary lignan excretion was observed in the flaxseed group (1,300%; P < 0.01) compared with placebo controls. The total intake of flaxseed was correlated with changes in c-erbB2 score (r = -0.373; P = 0.036) and apoptotic index (r = 0.495; P < 0.004). CONCLUSION: Dietary flaxseed has the potential to reduce tumor growth in patients with breast cancer.
Publication Types:
* Clinical Trial
* Randomized Controlled Trial
PMID: 15897583 [PubMed - indexed for MEDLINE]
RB
IP: 212.9.12.20 Reply With Quote
Hybrid Mode
